Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries by unknown
ARTICLE
Cost-effectiveness of pneumococcal vaccination for prevention
of invasive pneumococcal disease in the elderly: an update
for 10 Western European countries
S. M. A. A. Evers & A. J. H. A. Ament & G. L. Colombo &
H. B. Konradsen & R. R. Reinert & D. Sauerland &
K. Wittrup-Jensen & C. Loiseau & D. S. Fedson
Published online: 15 June 2007
# Springer-Verlag 2007
Abstract Pneumococcal vaccine is effective in preventing
invasive pneumococcal disease in adults ≥65 years of age,
but it is not widely used in Western Europe. In this study,
data from an earlier (1995) cost-effectiveness study on
Belgium, France, Scotland, Spain, and Sweden are updated,
and data on five new countries—Denmark, the UK
(specifically, England and Wales), Germany, Italy and The
Netherlands—are added. Epidemiological and economic
variables specific for each country were used, and it was
assumed that pneumococcal and influenza vaccines would
both be administered during the same physician visit. In the
base-case analyses, the cost-effectiveness ratios ranged
from €9239 to €23,657 per quality-adjusted life-year.
Because the incidence and mortality of invasive pneumo-
coccal disease were underestimated in most countries, a
country-by-country analysis was performed, assuming an
incidence of 50 cases per 100,000 population and mortality
rates of 20, 30 and 40%. For a mortality of 20%, the cost-
effectiveness ratios ranged from €4,778 to €17,093, and for
a mortality of 30%, they ranged from €3,186 to €11,395.
Pneumococcal vaccination to prevent invasive pneumococ-
cal disease in elderly adults was very cost-effective in all 10
countries. This evidence justifies the wider use of the
vaccine in Western Europe.
Introduction
Pneumococcal infection causes considerable morbidity and
mortality among elderly persons in developed countries [1].
Invasive or bacteremic pneumococcal disease (IPD) is the
most serious manifestation, and hospital treatment for
individual cases can be very costly. Prospective clinical
trials in elderly persons and their meta-analyses have
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attempted to show that 14- and 23-valent pneumococcal
polysaccharide vaccine prevents hospitalization of patients
for pneumococcal pneumonia or all-cause pneumonia, but
the results have been inconclusive [1, 2]. In contrast, several
observational studies have shown that the aggregate effec-
tiveness of pneumococcal vaccination is approximately 50–
70% in preventing hospitalization for IPD [1, 3–9].
The use of pneumococcal vaccine has increased recently in
some but not all developed countries [1, 10]. This is due to
better understanding of the clinical effectiveness of vaccina-
tion for elderly persons, but it also reflects better under-
standing of the cost-effectiveness of vaccination. The initial
cost-effectiveness studies of pneumococcal vaccination
focused on preventing pneumococcal pneumonia, but they
were unpersuasive because there was no evidence that
vaccination was clinically effective in preventing this
outcome [1, 11]. However, a study from the USA demon-
strated that pneumococcal vaccination of persons 65 years of
age and older would be cost-saving if it only prevented
hospitalization for pneumococcal bacteremia [12]. Because
of the difficulty in applying the conclusions from the U.S.
study to other countries, we conducted a cross-national
comparison for five Western European countries (Belgium,
France, Scotland, Spain, and Sweden) [13]. Using a common
model that incorporated epidemiological and economic
variables from each country, we showed that pneumococcal
vaccination to prevent invasive pneumococcal disease would
be very cost-effective in each country.
Several observers continue to insist that if widespread
use of pneumococcal vaccine is to be worthwhile, it must
be effective in preventing pneumococcal pneumonia; in
other words, nonbacteremic as well as bacteremic cases
[14–19]. Moreover, several Western European countries
still do not have recommendations for pneumococcal
vaccination of elderly persons and use very little vaccine
[1, 10]. For these reasons, we decided to update our earlier
cost-effectiveness study for the five original countries and
add five new countries: three countries with large popula-
tions (England and Wales, Germany, and Italy) and two
countries (Denmark and The Netherlands) for which good
epidemiological data were available.
Materials and methods
Model
We determined the cost-effectiveness of pneumococcal
vaccination in preventing hospitalization for invasive pneu-
mococcal disease (IPD) for elderly persons 65 years of age
and older in ten Western European countries. For five of these
countries (Belgium, France, Scotland, Spain, and Sweden),
we updated findings from our earlier 1995 cost-effectiveness
study [13]. For five new countries (Denmark, England and
Wales, Germany, Italy, and The Netherlands), we based our
findings on country-specific epidemiological and economic
data for 1 year. Because the clinical effectiveness and cost-
effectiveness of pneumococcal vaccination varies with age
[5, 13, 20], we performed separate analyses for persons 65–
74, 75–84, and 85 years of age and older, as well as for all
persons 65 years of age and older. Full details on our model
have been published previously [13].
We followed the principles of “reference case analysis” in
our evaluation [21]. We used a cohort model instead of a
more complex Markov model because transition probabili-
ties from one state to another over short time periods, which
are the basis of Markov modelling, are of little added value
when looking at vaccination strategies for IPD [22, 23]. We
considered two hypothetical cohorts: one that received
pneumococcal vaccine and one that did not. Both cohorts
were followed throughout their life spans. The life spans of
individuals in the cohorts without vaccination were calculated
on the basis of age-specific mortality rates (Population and
mortality. In: European Communities, 1995–2002. Eurostat
Data Shop, Health Statistics Netherlands, Voorburg, Nether-
lands, unpublished data). The life spans of those in the
vaccinated cohorts were affected only during the period when
vaccination was effective. The differences in life years
between cohorts with and without vaccination were calculated
for each age group for each year of life. Life years gained due
to vaccination were corrected for quality of life [13, 24]. This
resulted in the number of quality-adjusted life-years
(QALYs) gained by pneumococcal vaccination.
For each cohort, we calculated the differences in
hospitalization costs for IPD for each age group and each
year of life. The costs were a function of vaccination
effectiveness, hospital admission rate, average length of
stay (ALOS) and cost of one hospital day in each country.
The costs per QALY gained by vaccination were expressed
as cost-effectiveness ratios (CERs); i.e., the costs of
achieving one additional QALY in the vaccinated cohort.
The analyses reflected a societal point of view and all future
costs and health effects were discounted at 3% [13, 21].
Epidemiological variables
Data on the effectiveness of pneumococcal vaccination, the
incidence and mortality of IPD, the age-specific mortality
rates, and the age-specific differences in quality of life were
incorporated into the model [13]. We used estimates of
vaccination effectiveness that were obtained from an earlier
case-control study [5]. These estimates were used in the
earlier U.S. cost-effectiveness study [12], and we used them
in our earlier study [13]. We did not include adverse events
following vaccination in our analyses because they have
very little effect on the cost-effectiveness ratios [12].
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For 7 of the 10 countries we obtained data on the
incidence of IPD from population-based studies. Cases
were identified from hospital clinical microbiology labora-
tory reports. For each case, one or more isolates of
Streptococcus pneumoniae had been obtained from a
normally sterile extrapulmonary site (e.g., blood or cere-
brospinal fluid) during a single hospital stay. (Table 1) [1,
13]. Some reports also included information on the
outcome of hospital care (survival or death). For England
and Wales, we used data on incidence and mortality derived
from a published study [25]. For Germany we used data
derived from a recently completed study [26]. At the time
we conducted our analyses, there was no published
information on the incidence and mortality of IPD in Italy,
so we used estimates based on experience in the other nine
countries. Details on the sources of the epidemiological
variables are provided in our earlier publication [13] and in
the Appendix.
Economic variables
Given the differences in healthcare systems, cost estimates
varied from country to country (Table 2). We estimated
costs in euros. Wherever data were available, we based our
estimates on real costs (resources consumed) rather than on
charges [27]. We considered only direct medical costs for
vaccination and hospital care for IPD. We excluded
outpatient care costs for IPD and future costs of medical
care.
We obtained information on the retail price of the
vaccine in each country (Aventis Pasteur MSD, unpub-
lished data). In the base-case analyses, we assumed that
pneumococcal and influenza vaccines would be adminis-
tered during the same physician visit. Data from Spain and
The Netherlands indicated that pneumococcal vaccination
added to the administration of influenza vaccine incurred
additional administration costs of €2.59 and €4.02, respec-
tively (M. Postma, personal communication; the costs
included those associated with prescribing and billing, but
did not include labour costs for the injection). We set the
additional cost for pneumococcal vaccine administration at
€3.00 for all 10 countries.
We obtained information on the ALOS for IPD (or, if
this was not available, for pneumonia) for each country.
Because reimbursement systems are different in each
country, we could not adopt a uniform approach to
estimating the hospital costs for treating individual cases
of IPD (Table 2). In countries where hospital care is
financed according to diagnosis-related groups (DRGs), we
used DRG reimbursements for these estimates. In some
countries, we used reports of “special daily rates” for
financing specific hospital departments (e.g., internal
medicine). In other countries, where hospitals are financed
through global budgets, we used the average national costs
of a 1-day hospital stay. Where possible, our cost estimates
reflected acute hospital care, including costs for specialist
physicians, medications, and hospital overhead and invest-
ments. We did not consider days spent in intensive care
units and we excluded inpatient costs for nonbacteremic
pneumococcal pneumonia and long-term and psychiatric
care. Details on how we obtained cost estimates for each
country are provided in our earlier publication [13] and in
the Appendix.
Sensitivity analyses
We conducted both univariate and two-way sensitivity
analyses for all persons 65 years of age and older. In the
univariate analyses, we considered the cost-effectiveness of
administering pneumococcal vaccine by itself, increasing or
Table 1 Epidemiological data for invasive pneumococcal disease in the base-case analyses
Belgiuma Denmarkb England
and Walesb
Francea Germanyb Italyb The Netherlandsb Scotlanda Spaina Swedena
Incidence (per 100,000)
65–74 years 28.3 50.0 23.0 20.5 – – 42.0 21.8 40.0 22.7
75–84 years 41.2 72.9 37.0 28.6 – – 66.0 33.8 83.1 34.1
≥85 years 65.4 99.3 95.0 67.7 – – 92.1 62.9 74.5 49.2
≥65 years 35.6 63.9 36.0 29.3 50.0c 50.0c 55.1 29.5 57.2 34.1
Mortality (%)
65–74 years 12.8d 12.8 16.0 18.9 – – 15.7d 24.5d 8.0d 6.3
75–84 years 19.9d 31.4 20.0 20.6 – – 16.9d 40.0d 22.7d 12.9
≥85 years 26.3d 40.0 17.0 42.4 – – 17.8d 52.1d 26.8d 20.7
≥65 years 19.3d 22.8 18.0 25.8 20.0c 20.0c 16.6d 37.9d 17.6d 11.7
a Reported earlier [13]
b See Appendix for details
c No data were available for the three age groups individually. Estimates were used for all persons ≥65 years of age
d In the absence of specific data for IPD, data for pneumonia (International Classification of Diseases, 9th version, 480–486) were used
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lowering its price by €3.00, and increasing or lowering the
clinical effectiveness of vaccination (the upper and lower
bounds of the 95% confidence intervals of the point
estimates we used) [5, 12, 13]. We also considered a range
of estimates for the incidence (30–50 per 100,000 persons)
and mortality (20–40%) of IPD because reported rates for
these two variables differed substantially between the 10
countries [1, 13]. In addition, we examined the cost-
effectiveness of vaccination without adjusting for quality-
of-life and by changing the discount rate (0% and 5%). In
the two-way sensitivity analyses, we used an incidence of
50 cases per 100,000 persons and mortality rates of 20%,
30%, or 40% for all 10 countries. All other variables in the
two-way sensitivity analyses were those used in the base
case [13].
Updating the 1995 results
In our earlier report for Belgium, France, Scotland, Spain,
and Sweden, we reported cost-effectiveness results for the
year 1995 [13]. We updated results for these countries to
1999 using the (medical) price index and 1999 vaccine
prices. Age-specific population estimates and mortality
rates also were updated to 1999 using Eurostat data.
Results
Base-case analyses
Table 3 shows the results of the base-case analyses for the
three age groups and for all persons ≥65 years of age. There
was substantial variation in the cost-effectiveness ratios for
individual countries; for persons ≥65 years of age, they ranged
from €9,239 for Denmark to €23,657 for Sweden. In the eight
countries for which CERs for the three age groups could be
calculated, the CERs generally increased for older age groups.
Sensitivity analyses
Table 4 shows the results of the sensitivity analyses
performed for all persons ≥65 years of age. In the univariate
analyses, the CERs decreased substantially when the
incidence and mortality rates for IPD increased (Germany
and Italy excluded). The CERs were also sensitive to a
change in vaccination strategy, increasing when pneumo-
coccal vaccine was administered on a separate physician
visit instead of on the same visit as the influenza vaccine. In
addition, a lower level of vaccination effectiveness had a
marked effect on the CERs. Compared with results in the
Table 2 Estimated costs for each country included in the study
Belgiuma Denmarkb England
and Walesb
Francea Germanyb Italyb Netherlandsb Scotlanda Spaina Swedena
Vaccine-associated costsc
Vaccine price 17.9 16.6 14.4 13.6 27.1 25.8 17.5 14.4 14.4 7.5
Vaccine administration
Base cased 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0




285f 386 550 419f 300 288 260 472f 252f 375f
ALOS (days)
65–74 years 16.5g 11.9 14.0 14.4 15.1g 13.1g 12.0g 5.4g 11.6 11.0
75–84 years 19.1g 10.4 17.0 12.4 14.7g, h 16.0g 18.5g 7.6g 12.1 9.9
≥85 years 20.7g 9.7 14.0 11.8 14.7g, h 15.4g 27.9g 9.4g 9.8 10.7
≥65 years 18.7g 11.1 15.0 13.1 12.9g 14.9g 18.0g 7.8g 11.5 10.5
Cost per hospital
admission ≥65 yearsc
5,324 4,286 8,360 5,484 3,870 4,296 4,673 3,681 2,903 3,942
ALOS average length of stay
a Reported earlier [13]
b See Appendix for details
c For all countries, 1999 vaccine prices (in ) were used
d The base-case analyses assumed that pneumococcal vaccine would be administered during the same visit as the influenza vaccine
e The sensitivity analyses assumed that pneumococcal vaccine would be administered on a separate visit, not on the same visit as the influenza
vaccine
f The 1995 monetary data were discounted to 1999 figures using the medical price index
g In the absence of specific data for IPD, data for all pneumonia (ICD-9 code 480–486, see Appendix) were used
h Only figure provided for 75+
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base-case analyses, the CERs were less affected by changes
in the values for other variables (vaccine price, ALOS, no
quality-of-life adjustment, and discount rate).
The two-way sensitivity analyses for all 10 countries
assumed that the incidence of IPD was 50 cases per 100,000
elderly persons and the mortality rates were 20%, 30%, or 40%
(Table 4). For most countries, this led to substantial
reductions in the CERs compared with the CERs obtained
in the base-case analyses. Moreover, there was a striking
narrowing of the CER differences between all countries. For
example, when the mortality rate for IPD was 30%, the CERs
ranged from €3,186 in Sweden to €11,395 in Germany.
Table 3 Results of the base-case analyses, expressed as cost-effectiveness ratios in euros (1999) per QALY gained (see text for details)
Age group (years) Belgiuma Denmarkb England
and Walesb
Francea Germanyb Italyb Netherlandsb Scotlanda Spaina Swedena
65–74 19,324 8,056 13,820 14,023 –c –c 10,784 12,437 12,720 20,385
75–84 25,194 8,753 19,539 24,073 –c –c 17,456 14,319 8,878 23,490
≥85 57,219 23,786 41,664 23,743 –c –c 55,790 25,569 46,000 48,108
≥65 22,847 9,239 17,228 17,444 17,093 16,544 13,740 13,920 12,027 23,657
a Reported earlier [13]
b See Appendix for details
c Cost-effectiveness ratios could not be calculated for the age subgroups in these countries because data on the incidence of disease were not
available
Table 4 Results of the sensitivity analyses for all persons ≥65 years of age, expressed as cost-effectiveness ratios in euros (1999) per QALY
gained. See text for details
Belgiuma Denmarkb England
and Walesb
Francea Germanyb Italyb Netherlandsb Scotlanda Spaina Swedena
Base case 22,847c 9,239 17,228 17,444 17,093 16,544 13,740 13,920 12,027 23,657
1-way sensitivity analyses
Incidence
30/100,000 26,723 23,090 17,541 13,957 30,638 29,553 26,031 12,911 27,890 22,907
40/100,000 18,819 16,425 11,347 9,506 22,172 21,422 18,612 9,291 20,055 15,521
50/100,000ce 14,077 12,427 7,632 6,836 17,093 16,544 14,161 7,119 15,354 11,088
Mortality
20% 17,812 9,402 15,073 18,211 17,093 16,544 11,108 21,862 8,647 11,181
30% 11,875 6,268 10,050 12,142 11,395 11,029 7,406 14,574 5,765 7,454
40% 8,906 4,702 7,538 9,107 8,546 8,271 5,555 10,931 4,324 5,591
Separate visit
for vaccination
40,478 15,445 45,912 41,399 27,734 19,218 26,068 28,230 23,803 52,004
Vaccination effectiveness
Best case 15,020 5,512 9,556 11,123 12,480 12,052 8,749 9,218 7,498 14,330
Worst case 46,283 32,905 58,893 35,509 41,343 39,857 39,799 27,889 26,448 52,096
Vaccine price
−3Euro 18,832 7,299 12,837 13,568 15,071 14,513 11,108 11,220 9,394 15,046
+3Euro 26,862 11,178 21,618 21,321 19,116 18,575 16,372 16,619 14,660 32,267
ALOS 10 days 25,140 9,551 20,074 18,400 18,157 17,434 15,408 13,142 12,503 23,935
No QALY
adjustment
14,280 5,651 10,696 10,734 11,030 10,671 8,701 8,586 7,331 14,337
Discount rate
0% 16,076 6,219 10,350 12,145 12,230 11,823 9,090 10,250 8,422 16,337
5% 27,735 11,381 22,018 21,266 20,697 20,034 17,057 16,546 14,631 28,848
2-way sensitivity analysis
Incidence 50/100,000
Mortality20% 10,451 11,511 6,533 6,779 17,093 16,544 11,345 10,428 9,187 4,778
Mortality30% 6,968 7,674 4,356 4,520 11,395 11,029 7,564 6,952 6,124 3,186
Mortality40% 5,226 5,755 3,268 3,390 8,546 8,271 5,673 5,214 4,593 2,390
ALOS average length of stay, QALY quality-adjusted life-year
a Reported earlier [13]
b See Appendix for details
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Discussion
The results of our study for five new countries confirm
those obtained for the five countries included in our earlier
report [13]. They indicate that pneumococcal vaccination of
elderly people to prevent IPD is a cost-effective interven-
tion for each of these 10 Western European countries. Other
studies reported from The Netherlands [28], France [29],
and England and Wales [25] have reached similar con-
clusions, as have a report from Canada [30] and an earlier
report from the USA [12]. A more recent report from the
USA indicates that for preventing IPD alone, extending
pneumococcal vaccination to people ≥50 years of age also
would be cost-effective [31].
In our base-case analyses, we found threefold differences
in the CERs between the 10 countries we studied. The
univariate sensitivity analyses showed that these differences
reflected different values for the epidemiological and
economic variables for each country. For the economic
variables, lower CERs were found in Denmark and Scot-
land, where costs for hospital admissions were low,
whereas the reverse was found in England and Wales,
where the hospital costs were high. Different vaccine prices
had less effect on the CERs, although, as expected,
requiring separate visits for pneumococcal and influenza
vaccination dramatically increased the CERs in all
countries. Evidence from clinical practice, however, indi-
cates that 75–85% of pneumococcal vaccinations are given
during the influenza vaccination season, presumably during
the same physician visit [32], and that doing so is safe and
does not compromise antibody response to either vaccine
[33]. However, economic variables were less important
than epidemiological variables in accounting for differences
in the CERs between countries.
For the nine countries (excluding Italy) for which we had
data, the incidence rates for IPD among elderly persons
used in our base-case analyses varied considerably (Table 1).
Substantial variations (2- to 3-fold) in the incidence of IPD
have been reported between and within developed countries
[1]. They are thought to be due primarily to different rates
of obtaining blood cultures in people hospitalized with
community-acquired pneumonia, as evidenced by reports of
steadily increasing rates of pneumococcal bacteremia over
time despite constant rates of pneumococcal meningitis [1,
34]. Several studies from the USA, Canada, Australia, and
Israel have reported rates of IPD among the elderly of ≥50/
100,000 [1]. For the six countries in our study that reported
lower rates (≤36/100,000), it is almost certain that the true
incidence of IPD was underestimated. After our analyses
were completed, a study was published from Italy indicat-
ing that in two regions the incidence of IPD among people
≥65 years of age was 5.7 (Piemonte) and 0.2 (Puglia) per
100,000 [35]. These rates are uniquely lower than those
reported in all other developed countries and strongly
suggest a serious degree of underreporting. For this reason,
we believe it was reasonable to assume an incidence of 50/
100,000 for elderly people in Italy.
We obtained epidemiological data on IPD mortality rates
for people ≥65 years of age for only 4 of the 10 countries,
and had to use rates for all-cause pneumonia or estimates
(20%) for the other 6 (Table 1). In five of the countries, the
mortality rates we used were <20%, rates considerably
lower than those reported in epidemiological studies from
several European countries (France 28%, The Netherlands
31%, Scotland 43%, Spain 24%, and Sweden 33%) [1].
Moreover, in published case series, IPD mortality rates
among the elderly have ranged from 18 to 51%, but in
almost all instances they have been above 20% and, in
many instances, above 30% [1]. In two recent reports of
pneumococcal bacteremia in elderly people, the 28- to
30-day mortality rate in both studies was 22% [36, 37; Y.
L. Yu, personal communication]. These findings indicate
that for the countries for which we used base-case mortality
rates of <20%, we probably underestimated the true impact
of IPD mortality.
Because the incidence and mortality rates used in the
most of the base-case analyses were lower than those
reported in more reliable empirical studies, the CERs we
obtained for these countries most likely underestimate the
cost-effectiveness of pneumococcal vaccination. When
more plausible assumptions for incidence (50/100,000)
and mortality (20%, 30%, or 40%) were used in the two-
way sensitivity analyses, the CERs changed substantially.
For example, in the base-case analysis for Sweden, where
we used an incidence of 34/100,000 and a mortality of
12%, the resulting CER was €23,657, but in the two-way
sensitivity analysis it fell to €4,778 (mortality 20%). For
France, increasing the incidence from 29.3 to 50/100,000
led to a decrease in the CERs from €17,444 to €6,534
(mortality 20%) and €4,357 (mortality 30%). (The mortality
in the base-case analysis for France was 25.8%.) For The
Netherlands, increasing the base-case mortality rate
(16.1%) decreased the CERs to €11,345 (mortality 20%)
or €7,564 (mortality 30%). The base-case analyses for
Germany and Italy assumed an incidence of 50/100,000 and
a mortality of 20%, but increasing mortality to 30%
reduced the CERs to approximately €11,000. For Denmark,
the two-way sensitivity analysis had little effect on the
CERs because the values for incidence and mortality were
similar to those used for the base-case analysis.
Our results were similar to those obtained in other cost-
effectiveness studies. Dutch investigators used epidemio-
logical and economic variables similar to ours, and all
CERs in their base-case and univariate analyses were <
€16,000 [28]. French investigators also used epidemiolog-
ical and economic variables similar to ours, but the results
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of their study cannot be compared with ours because their
CERs were expressed in terms of saving one more life
instead of life-years gained (LYG) or QALYs [29]. In a
cost-effectiveness study reported for England and Wales
[25], the investigators obtained a CER of €13,761 per LYG
(base-case analysis, £9,477; £1.00=€0.62), a value lower
than our CER of €17,228. Their study differed from ours in
several ways. For vaccine efficacy, they used estimates of
20% for high-risk individuals (∼10% of all subjects) and
65% for non-high-risk subjects and assumed that protection
was constant over 5- to 6.5-year periods. These estimates
are at odds with those used in other cost-effectiveness
studies [12, 13, 28, 29] and fail to reflect the well-known
decline in clinical protection and antibody levels that occur
over the 5-year period following vaccination [1, 5]. The
investigators also assumed that every patient with IPD
would receive antibiotic treatment before hospital admis-
sion, an assumption that for community-acquired pneumo-
nia (∼90% of cases of IPD are bacteremic pneumonia) is
not supported by empirical evidence [1]. Their cost
estimates for an episode of hospital care and vaccination
were lower than ours, and they reported their results as
CERs per LYG, not QALYs. Each of their assumptions
would have given lower CERs than were obtained with our
assumptions. Nonetheless, in both their base-case analysis
and ours, pneumococcal vaccination was found to be cost-
effective. Moreover, when we used a more plausible
incidence of IPD of 50/100,000 and a mortality of 20%
(they used 18%), the CER for England and Wales decreased
to €6,633 per QALY despite our more conservative
assumptions for several important variables. A more recent
study examined the cost-effectiveness of pneumococcal
vaccination from the perspective of a developed country
and assumed an effectiveness of 50% against both IPD
morbidity and mortality [38]. For elderly people, the net
cost to society was £2,500 per year of life saved.
Our study has several potential limitations, most of
which reflect uncertainty about some of the variables. Our
estimates of hospital costs were conservative and, we
believe, reliable, but our estimates for the incidence and
mortality of IPD were more uncertain. In all instances,
however, the available data tended to underestimate rather
than overestimate these parameters, and we compensated
for this in our two-way sensitivity analyses. We used data
from one observational study as the source of our estimates
of vaccination effectiveness [5], but many observers
discount or ignore such findings [14–19, 38]. However,
there are good reasons to accept these data [1, 2], and they
have the advantage of reflecting vaccination effectiveness
in the real world rather than vaccine efficacy as determined
under the controlled conditions of a clinical trial. We did
not consider indirect costs, although to some extent they are
implicit in our adjustments for quality of life, nor did we
consider unrelated future medical care costs, although some
experts believe they should be included [11]. We estimated
the health gains from vaccination on the basis of average
life expectancy, knowing that because people more likely to
develop IPD might have lower-than-average life expectancy,
we might have overestimated the cost-effectiveness of
vaccination [11]. However, we excluded all costs for
outpatient care, ICU care, and hospitalization for non-
bacteremic pneumococcal pneumonia; including any one of
these variables would have improved the CERs [39].
Several recent reports have shown that among patients
hospitalized with community-acquired pneumonia, previ-
ous pneumococcal vaccination was associated with a lower
incidence of pneumococcal bacteremia [40], fewer compli-
cations and shorter hospital stays [40, 41], and lower rates
of pneumonia mortality [42] and all-cause mortality [41].
One report even suggested that pneumococcal vaccina-
tion significantly reduced hospitalization for community-
acquired pneumonia by 26% [42]. These findings provide
further evidence that the cost-effectiveness estimates we
obtained were conservative and that they can serve as a
guide to policy-makers in the countries included in our
analysis.
We emphasize that our findings are based on country-
specific economic and, in most cases, epidemiological data.
Each country has its own healthcare system and healthcare
financing system, and this will affect the results of any cost-
effectiveness analysis. For this reason, attempts to generalize
our findings to other countries in Western Europe should
proceed cautiously.
Although several studies of the cost-effectiveness of
pneumococcal vaccination have been published, there is
little evidence that they have had an effect on policy
decisions, a finding that is true of most cost-effectiveness
studies [43]. The increase in pneumococcal vaccination that
began in several Western European countries in the mid-
1990s occurred in the absence of country-specific evidence
that vaccination would be cost-effective [1]. In several of
these countries, there still are no data on the incidence of
IPD [1], and in many countries uncertainty about vaccina-
tion effectiveness still is widespread [14–19, 44]. In
addition, there is uncertainty about the marginal health
benefits of pneumococcal vaccination above those of
influenza vaccination [44, 45]. Why this is regarded as an
important question is unclear, because IPD continues to
occur year-round in countries that already have high levels
of influenza vaccine use [46]. The clinical trials that have
attempted to evaluate the incremental benefit of pneumo-
coccal vaccination in people who have received influenza
vaccine have been inadequate and provide no guidance [1,
2]. Nevertheless, there is solid evidence from observational
studies that when used together, the clinical and economic
benefits of the two vaccines are additive [47, 48].
Eur J Clin Microbiol Infect Dis (2007) 26:531–540 537
When static models such as ours are used to assess the cost-
effectiveness of pneumococcal vaccination, they present few
methodological problems [49]. However, the introduction of
pneumococcal conjugate vaccine for children in the USA has
produced a measurable level of herd immunity and has led to
a decrease in the incidence of vaccine-type IPD in older
adults [50]. Thus, more dynamic models may be required for
future cost-effectiveness analyses in countries where both the
polysaccharide and conjugate vaccines are used [49]. For
now, however, when only the polysaccharide vaccine is
being used in most Western European countries, there is
compelling evidence for its clinical effectiveness and cost-
effectiveness in elderly people. This evidence more than
justifies its widespread use.
Acknowledgements The authors gratefully acknowledge the con-
tributions of R. Baltussen, P. Christie, D. de Graeve, G. Duru, J.
Gaillat, B. Jonsson, A. Ortqvist, C. Rigaud-Bully, A. Salazar Cifre,
and J. Verhagen to the cost-effectiveness study for the first five
countries [12]. We thank J. van Emmerik for assistance in developing
the cohort model, E. Brounts and M. Hübben for the literature review,
and Nathalie Largeron for assistance with the current study. Our work
was made possible by an unrestricted grant from Aventis Pasteur MSD
(now Sanofi Pasteur MSD).
Appendix
References
1. Fedson DS, Musher DM (2004) Pneumococcal polysaccharide
vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines. Saunders,
Philadelphia, pp 529–588
2. Fedson DS, Liss C (2004) Precise answers to the wrong question:
prospective clinical trials and the meta-analyses of pneumococcal
vaccine in elderly and high-risk adults. Vaccine 22:927–946
Table 5 Sources of country-specific data for the five additional
countries included in the present study (see earlier report for sources
of data for Belgium, France, Scotland, Spain, and Sweden [ 13])
Country Data
Incidence of IPD
Denmark Statens Serum Institut for 1999
England Input data from Melegaro and Edmunds [25];
constructed weighted average for all age groups
Germany Incidence of IPD in North-Rhine Westphalia in
2001–2003. Reinert [26]
Italy Plausible figures based on literature review by
Fedson and Musher [1]
The
Netherlands
Ongoing surveillance of routine isolates in regional
healthcare laboratories; unpublished data of H. de
Neeling, National Institute of Public Health
Department for Health Service Research
Mortality rate of IPD
Denmark National Board of Health’s National Patient Register
(Lands-patientregistret). Diagnosis codes: G001and
A403 for 1999
England Input data from Melegaro and Edmunds [25];
constructed weighted average for all age groups
Germany Plausible figures based on literature review by Fedson
and Musher [1]




Data for pneumococcal pneumonia were used as proxy




Denmark National Board of Health’s National Patient Register
(Lands-patientregistret). Diagnosis codes: G001and
A403 for 1999
England Input data from Melegaro and Edmunds [25];
constructed weighted average for all age groups
Germany Data for pneumococcal pneumonia were used as proxy
(Federal Health Monitoring System, Germany)




Data for pneumococcal pneumonia were used as proxy
(National Hospital Registration)
GP costs
Belgium GP fee for each consultation for vaccination, official
tariff, Ministry of Health 1997
Denmark Charge per standard consultation at GP National
Health Insurance Service
England Figure for 1999/2000 Office of Health Economics,
Compendium for Health Statistics 2000 (GP costs =
14 British pounds [conversion factor, 1 euro = 0.62
British pounds])
Germany Average costs of GP consultation based on data of the
Regional Association of SHI-physicians for Westfalen




Average costs for GP consultation according to the
Dutch guidelines, Oostenbrink, et al 2000,
Handleiding voor kostenonderzoek. Amstelveen:
College voor Zorgverzekeringen.
Hospital care costs
Denmark Cost per day in DRG charge, calculated from the DRG
charge for pneumonia and pleurisy (DRG 90) in1999,
Ministry of Health, DRG catalogue, 2000
England Chartered Institute for Public Finance and Accounting
(CIPFA) Health Database Average costs for infectious
disease (costs = 341 British pounds [conversion
factor, 1 euro = 0.62 British pounds])
Germany Cost of 1 hospital day acute care, Federal Health
Monitoring System, Germany
Italy Average cost per hospital day in Italy based on DRG
(089, 090, 091) Ministry of Health
The
Netherlands
Real costs per hospital day based on the calculation of
the University Hospital Maastricht, unpublished data,
T. van Asselt
IPD invasive pneumococcal disease, ALOS average length of stay,
DRG diagnosis-related groups
538 Eur J Clin Microbiol Infect Dis (2007) 26:531–540
3. Shapiro ED, Clemens JD (1984) A controlled evaluation of the
protective efficacy of pneumococcal vaccine for patients at high risk
of serious pneumococcal infections. Ann Intern Med 101:325–330
4. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC,
Schwartz JS (1988) The clinical effectiveness of pneumococcal
vaccine in the elderly. Ann Intern Med 108:653–657
5. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V,
Margolis A, Adair RK, Clemens JD (1991) The protective
efficacy of polyvalent pneumococcal polysaccharide vaccine. N
Engl J Med 325:1453–1460
6. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV,
Facklam RR (1993) Pneumococcal polysaccharide vaccine effi-
cacy. An evaluation of current recommendations. JAMA
270:1826–1831
7. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal
KA, Anglim AM (1995) Preventing pneumococcal bacteremia in
patients at risk. Results of a matched case-control study. Arch
Intern Med 155:2336–2340
8. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams
AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW, and
the Vaccine Safety Datalink (2003) Effectiveness of pneumococ-
cal polysaccharide vaccine in older adults. N Engl J Med
348:1747–1755
9. Dominguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L,
Ciruela P, Fenoll A, Casal J (2005) Effectiveness of pneumococcal
vaccination for elderly people in Catalonia, Spain: a case-control
study. Clin Infect Dis 40:1250–1257
10. Fedson DS (1998) Pneumococcal vaccination in the United States
and 20 other developed countries, 1981–1996. Clin Infect Dis
26:1117–1123
11. Beutels P, Postma MJ (2001) Economic evaluations of adult
pneumococcal vaccination strategies. Expert Rev Pharmacoeco-
nomics Outcomes Res 1:47–58
12. Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean
AM, Plouffe JF, Cetron MS, Butler JC (1997) Cost-effectiveness
of vaccination against pneumococcal bacteremia among elderly
people. JAMA 278:1333–1339
13. Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D,
Ortqvist A, Jonsson B, Verhaegen J, Gaillat J, Christie P, Cifre
AS, Vivas D, Loiseau C, Fedson DS (2000) Cost-effectiveness of
pneumococcal vaccination of older people: a study in 5 western
European countries. Clin Infect Dis 31:444–450
14. Hirschmann JV, Lipsky BA (1994) The pneumococcal vaccine
after 15 years of use. Arch Intern Med 154:373–377
15. Hak E, Grobbee DE, van Essen GA, Buskens E, Verheij TJ (2000)
Pneumococcal vaccination of the elderly: do we need another
trial? Arch Intern Med 160:1698–1699
16. Moeller K, Kronberg G, Dirksen A (2001) Is polysaccharide
pneumococcal vaccine effective in adults? (Danish) Ugeskr
Laeger 163:6112–6117
17. Jefferson TO, Demichelli V (2002) Polysaccharide pneumococcal
vaccines. BMJ 235:292–293
18. Mangtani P, Cutts F, Hall AJ (2003) Efficacy of polysaccharide
pneumococcal vaccine in adults in more developed countries: the
state of the evidence. Lancet Infect Dis 3:71–78
19. Jonkers RE, Boersma WG (2003) Pneumococcal vaccination in
adults (Dutch). Ned Tijdschr Geneeskd 147:425–428
20. Baltussen RPMH, Ament AJHA, Leidl RM, van Furth R (1997)
Cost-effectiveness of vaccination against pneumococcal pneumo-
nia in The Netherlands. Eur J Public Health 7:153–161
21. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB
(1996) Recommendations of the panel on cost-effectiveness in
health and medicine. JAMA 276:1253–1258
22. Moskowitz AJ, Dunn VH, Lau J, Pauker SG (1984) Can
“hypersimplified” decision trees be used instead of Markov
models? Med Decis Making 4:530
23. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA
(1997) Primer on medical decision analysis: Part 1-getting started.
Med Decis Making 17:123–125
24. Erikson P, Wilson R, Shannon I (1995) Years of healthy life.
Healthy people 2000. Stat Notes no. 7. DHHS publication no.
(PHS) 95-1237 4-1484. National Center for Health Statistics,
Hyattsville, MD, pp 1–15
25. Melegaro A, Edmunds WJ (2004) The 23-valent pneumococcal
polysaccharide vaccine. Part II. A cost-effectiveness analysis for
invasive disease in the elderly in England and Wales. Eur J
Epidemiol 19:365–375
26. Reinert RR (2005) Invasive pneumococcal disease in adults in
North-Rhine Westphalia, Germany, 2001–2003. Clin Microbiol
Infect 11:985–991
27. Finkler SA (1982) The distinction between costs and charges. Ann
Intern Med 196:102–109
28. Postma MJ, Heijnen M-LA, Jager JC (2001) Cost-effectiveness
analysis of pneumococcal vaccination for elderly individuals in
The Netherlands. Pharmacoeconomics 19:215–222
29. Amazian K, Nicoloyannis N, Colin C, Nguyen VH, Duru G
(2002) Cost-effectiveness analysis of pneumococcal vaccination
of older people in France. Med Mal Infect 32:405–417
30. Conseil d’Evaluation des Technologies de la Sante du Quebec
(1999) Cost-effectiveness and cost-utility of a pneumococcal
immunization program in Quebec. CETS, Montreal, Report no.
CETS 98-4RE
31. Sisk JE, Whang W, Butler JC, Sneller V-P, Whitney CG (2003)
Cost-effectiveness of vaccination against invasive pneumococcal
disease among people 50 through 64 years of age: role of
comorbid conditions and race. Ann Intern Med 138:960–968
32. Peetermans WE, Lacante P (1999) Pneumococcal vaccination by
general practitioners: an evaluation of current practice. Vaccine
18:612–617
33. Fletcher TJ, Tunnicliffe WS, Hammond K (1997) Simultaneous
immunisation with influenza vaccine and pneumococcal polysac-
charide vaccine in patients with chronic respiratory disease. BMJ
314:1663–1665
34. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ,
Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid
MB, Andremont A, Klugman KP, and the International Pneumo-
coccal Study Group (2003) An international prospective study of
pneumococcal bacteremia: correlation with in vitro resistance,
antibiotics administered, and clinical outcome. Clin Infect Dis
37:230–237
35. D’Ancona F, Salmaso S, Barale A, Boccia D, Lopalco PL, Rizzo
C, Monaco M, Massari M, Demicheli V, Pantosti A, and the
Italian PNC-Euro Working Group (2005) Incidence of vaccine
preventable pneumococcal invasive infections and blood culture
practices in Italy. Vaccine 23:2494–2500
36. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J (2004)
Prospective observational study of bacteremic pneumococcal
pneumonia: effect of discordant therapy on mortality. Crit Care
Med 32:625–631
37. Sleeman K, Knox K, George R, Miller E, Waight P, Griffiths D,
Efstratiou A, Broughton K, Mayon-White RT, Moxon ER, Crook
DW, Public Health Laboratory Service, and the Oxford Pneumo-
coccal Surveillance Group (2001) Invasive pneumococcal disease
in England and Wales: vaccination implications. J Infect Dis
183:239–246
38. Mangtani P, Roberts JA, Hall AJ, Cutts FT (2005) An economic
analysis of a pneumococcal vaccine programme in people aged
over 64 years in a developed country setting. Int J Epidemiol
34:565–574
39. Ament A, Fedson DS, Christie P (2001) Pneumococcal vaccina-
tion and pneumonia; even a low level of clinical effectiveness is
highly cost-effective. Clin Infect Dis 33:2078–2079
Eur J Clin Microbiol Infect Dis (2007) 26:531–540 539
40. Mykietiuk A, Carratala J, Dominguez A, Manzur A, Fernandez-
Sabe N, Dorca J, Tubau F, Manresa F, Gudiol F (2006) Effect of
prior pneumococcal vaccination on clinical outcome of hospital-
ized adults with community-acquired pneumococcal pneumonia.
Eur J Clin Microbiol Infect Dis 25:457–562
41. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J
(2006) Prior pneumococcal vaccination is associated with reduced
death, complications and length of stay among hospitalized adults
with community-acquired pneumonia. Clin Infect Dis 42:1093–1101
42. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova
A, Rodriguez T, Llor C, and the EVAN Study Group (2006)
Protective effects of the 23-valent pneumococcal polysaccharide
vaccine in the elderly population: the EVAN-65 study. Clin Infect
Dis 43:860–868
43. Oliver A, Mossialos E, Robinson R (2004) Health technology
assessment and its influence on health-care priority setting. Int J
Technol Assess Health Care 20:1–10
44. Kullberg BJ (2004) Vaccination against pneumococcal infections
in elderly persons and immunocompromised adults. Dutch Health
Council. (Dutch). Ned Tijdschr Geneeskd 149:871–874
45. Assendelft WJ, Scholten RJ, Offringa M (2004) Pneumococcal
vaccination for the elderly in The Netherlands? Assessment of the
quality and content of available comparative studies. Neth J Med
62:36–44
46. The macroepidemiology of influenza vaccination (MIV) study
group (2005) The macroepidemiology of influenza vaccination in
56 countries, 1997–2003 Vaccine 23:5133–5143
47. Nichol KL, Baken L, Wuorenma J, Nelson A (1999) The health
and economic benefits associated with pneumococcal vaccination
of elderly persons with chronic lung disease. Arch Intern Med
159:2437–2442
48. Kelly H, Attia J, Andrews R, Heller RF (2004) The number needed
to vaccinate (NNV) and population extensions of the NNV:
comparison of influenza and pneumococcal vaccine programmes
for people aged 65 years and over. Vaccine 22:2192–2198
49. Beutels P, van Doorslaer E, van Damme P, Hall J (2003)
Methodological issues and new developments in the economic
evaluation of vaccines. Exp Rev Vaccines 2:949–960
50. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley
MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler
J, Cieslak PR, Whitney CG, and the Active Bacterial Core
Surveillance Team (2005) Changing epidemiology of invasive
pneumococcal disease among older adults in the era of pediatric
pneumococcal conjugate vaccine. JAMA 294:2043–2051
540 Eur J Clin Microbiol Infect Dis (2007) 26:531–540
